Liquidia Chairman Sold $2.5M in Shares — Not a Red Flag
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Stephen M. Bloch, Chairman of Liquidia's Board, sold 70,234 shares worth approximately $2.53 million in open-market transactions disclosed via SEC Form 4
- The sale represented just 3.02% of Bloch's aggregate holdings, and it was his only open-market sale in the relevant historical window, with no established pattern of regular selling
- All 70,234 shares were sold indirectly through Canaan VIII, L.P., while Bloch's direct stake of 65,712 shares remained untouched
- Liquidia closed 2025 with $158.3 million in sales — more than 11x the $14 million reported in 2024 — and posted Q4 net income of $14.6 million, reversing a $38.5 million year-ago loss
- The company's stock hit a 52-week high of $46.67 in February 2026, but its price-to-sales ratio fell to roughly 21, a low point for the trailing year
- CEO Roger Jeffs called Liquidia's YUTREPIA product 'one of the top specialty drug launches over the past five years,' reinforcing the company's commercial momentum
Why it matters: A $2.5M insider sale could spook shareholders, but the 3% size, lack of a selling history, and indirect-entity structure suggest routine portfolio management rather than a loss of conviction — particularly notable given Liquidia's 11x revenue jump and second straight profitable quarter, which have compressed the stock's P/S ratio to a one-year low of ~21.
Ask SkimNews
